

# Cyrus D Agarabi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4216905/publications.pdf>

Version: 2024-02-01

19  
papers

373  
citations

933447

10  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

418  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing. Trends in Biotechnology, 2019, 37, 253-267.	9.3	113
2	Fermentanomics informed amino acid supplementation of an antibody producing mammalian cell culture. Biotechnology Progress, 2013, 29, 745-753.	2.6	36
3	Fermentanomics: Relating quality attributes of a monoclonal antibody to cell culture process variables and raw materials using multivariate data analysis. Biotechnology Progress, 2015, 31, 1586-1599.	2.6	30
4	Bioreactor Process Parameter Screening Utilizing a Plackett-Burman Design for a Model Monoclonal Antibody. Journal of Pharmaceutical Sciences, 2015, 104, 1919-1928.	3.3	29
5	Characterization of mammalian cell culture raw materials by combining spectroscopy and chemometrics. Biotechnology Progress, 2017, 33, 1127-1138.	2.6	24
6	Impact of media and antifoam selection on monoclonal antibody production and quality using a high throughput micro-bioreactor system. Biotechnology Progress, 2018, 34, 262-270.	2.6	22
7	Exploring the linkage between cell culture process parameters and downstream processing utilizing a plackett-burman design for a model monoclonal antibody. Biotechnology Progress, 2017, 33, 163-170.	2.6	17
8	An ICP-MS platform for metal content assessment of cell culture media and evaluation of spikes in metal concentration on the quality of an IgG3:1 <sup>9</sup> monoclonal antibody during production. Journal of Pharmaceutical and Biomedical Analysis, 2019, 162, 91-100.	2.8	15
9	Metabolic responses and pathway changes of mammalian cells under different culture conditions with media supplementations. Biotechnology Progress, 2018, 34, 793-805.	2.6	14
10	Multivariate data analysis of growth medium trends affecting antibody glycosylation. Biotechnology Progress, 2020, 36, e2903.	2.6	14
11	Effect of amino acid supplementation on titer and glycosylation distribution in hybridoma cell cultures—Systems biology-based interpretation using genome-scale metabolic flux balance model and multivariate data analysis. Biotechnology Progress, 2016, 32, 1163-1173.	2.6	10
12	Real-time quantification and supplementation of bioreactor amino acids to prolong culture time and maintain antibody product quality. Biotechnology Progress, 2019, 35, e2894.	2.6	9
13	Mycoplasma Clearance and Risk Analysis in a Model Bioprocess. PDA Journal of Pharmaceutical Science and Technology, 2017, 71, 99-114.	0.5	7
14	Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells. Journal of Visualized Experiments, 2018, , .	0.3	7
15	Impacts of intentional mycoplasma contamination on CHO cell bioreactor cultures. Biotechnology and Bioengineering, 2019, 116, 3242-3252.	3.3	7
16	High Performance Size Exclusion Chromatography and High-Throughput Dynamic Light Scattering as Orthogonal Methods to Screen for Aggregation and Stability of Monoclonal Antibody Drug Products. Journal of Pharmaceutical Sciences, 2020, 109, 3330-3339.	3.3	7
17	Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events. Biotechnology and Bioengineering, 2020, 117, 2802-2815.	3.3	6
18	Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System. Journal of Visualized Experiments, 2019, , .	0.3	5

#	ARTICLE	IF	CITATIONS
19	Failure Mode Identification of Insulin Drug Products – Impact of Relevant Stress Conditions on the Quality of the Drug. Journal of Pharmaceutical Sciences, 2022, 111, 2451-2457.	3.3	1